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Abstract
Genome-wide gene expression profiling has become standard for assessing potential liabilities as well as for elucidating
mechanisms of toxicity of drug candidates under development. Analysis of microarray data is often challenging due to the
lack of a statistical model that is amenable to biological variation in a small number of samples. Here we present a novel
non-parametric algorithm that requires minimal assumptions about the data distribution. Our method for determining
differential expression consists of two steps: 1) We apply a nominal threshold on fold change and platform p-value to
designate whether a gene is differentially expressed in each treated and control sample relative to the averaged control
pool, and 2) We compared the number of samples satisfying criteria in step 1 between the treated and control groups to
estimate the statistical significance based on a null distribution established by sample permutations. The method captures
group effect without being too sensitive to anomalies as it allows tolerance for potential non-responders in the treatment
group and outliers in the control group. Performance and results of this method were compared with the Significant
Analysis of Microarrays (SAM) method. These two methods were applied to investigate hepatic transcriptional responses of
wild-type (PXR
+/+) and pregnane X receptor-knockout (PXR
2/2) mice after 96 h exposure to CMP013, an inhibitor of b-
secretase (b-site of amyloid precursor protein cleaving enzyme 1 or BACE1). Our results showed that CMP013 led to
transcriptional changes in hallmark PXR-regulated genes and induced a cascade of gene expression changes that explained
the hepatomegaly observed only in PXR
+/+ animals. Comparison of concordant expression changes between PXR
+/+ and
PXR
2/2 mice also suggested a PXR-independent association between CMP013 and perturbations to cellular stress, lipid
metabolism, and biliary transport.
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Introduction
Microarrays are now the preferred technology in many
biological applications ranging from functional characterization
of genes and pathways to classification of disease signatures for
diagnostic and prognostic purposes. Within the field of toxicoge-
nomics, genome-wide gene expression data have been widely used
to assess potential toxicity as well as to elucidate mechanisms of
toxicity of drug candidates [1–4]. The growing number of
applications and wide adoption of microarray data have in turn
fueled the development of analysis methods devised to extract
information from these datasets [5]. While earlier studies were
often complicated by technical inconsistencies, microarray data
have become significantly more reliable and reproducible [6,7]. In
fact, analysis of reference mRNA obtained from mixed rat tissues
processed over a multi-year period by Amgen and several external
facilities has consistently shown relatively high sensitivity and
specificity [8,9]. However, even with highly improved technology,
the microarray community continues to struggle with the analysis,
interpretation, and extraction of biologically relevant knowledge
from the large volume of expression measurements. Much work
has been invested in developing models and algorithms for these
purposes and their levels of complexity have tended to increase
over time. Unfortunately, however, the increased level of
algorithmic complexity does not always translate to improved
biological understanding [10]. In particular, many model-driven
methods often assume certain distributions for the data that are
either not true or not easily verifiable. Furthermore, while most
existing statistical models perform well with simulated data, they
often are too sensitive to what is generally considered an
acceptable level of biological variation.
Our goal here is to devise a method that requires fewer
assumptions about intensity distribution of genes and therefore can
be described with an intuitive mathematical model. The method is
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15595meant to capture group effects without being too sensitive to
anomalies in a small subset of subjects. Such tolerance is necessary
because biological variation is typically large due to uncontrollable
variables resulting both from inherent heterogeneity and technical
procedures during the course of experiments. Therefore, it may
not be desirable to penalize large variations in the amplitude of
gene expression as long as the changes relative to the control group
are in the same direction across the majority of animals. Our
approach leverages the platform p-value [11] and fold change
cutoffs to designate whether changes in a gene constitute
biologically differential expression between each treated sample
relative to the vehicle-control pool. The significance of the group
effect for the gene is then estimated by comparing the number of
changed samples observed between the two groups. In particular,
the algorithm involves two steps:
1. A nominal threshold of 1.25 fold change and platform p-value
[11] of 0.1 were used to designate whether a gene displays
differential expression in each treated and control sample
relative to the averaged control pool.
2. False discovery rate was estimated based on the probability of
encountering the observed number of differentially expressed
samples in the treated group, given the total number of
observed differentially expressed samples in both groups, under
the empirically determined distribution derived from the null
hypothesis that the differentially expressed samples are equally
distributed in both groups.
Thresholds on fold change and p-values were set to values we
believed would likely translate to biological significance from our
experience with similar toxicology studies. Performance of this
method was compared with the popular microarray analysis
method Significant Analysis of Microarrays (SAM) [12]. The two
methods were applied to investigate the role of pregnane X
receptor (PXR) in hepatic toxicities induced by CMP013, a small
molecule inhibitor of b-secretase (BACE1) enzyme. BACE1, the
first of the two proteases that cleaves amyloid precursor protein, is
believed to be a prime drug target for Alzheimer’s disease [13–15].
Early toxicology screening with CMP013 in rats revealed
prominent effects in the liver including hepatomegaly (liver weight
nearly 2x above control) with histological correlates of increased
mitotic figures, vacuolation, and hepatocellular hypertrophy.
In vitro data suggested that CMP013 might be an agonist for
PXR and we hypothesized that this nuclear receptor was at least
partially responsible for the potent hepatic effects noted in 4-day
rat toxicology studies. To further evaluate the role of PXR in
mediating mechanisms of toxicity by CMP013, a subsequent 4-day
toxicology study with CMP013 was carried out with wild type
(C57Bl/6) and PXR-knockout (C57Bl/6NTac) mice (Table 1) to
confirm that mice respond to CMP013 in a manner similar to rats.
Following confirmation of CMP013-mediated hepatic effects in
C57Bl/6 mice (Figure 1), gene expression data was generated from
liver tissue of these animals for mechanistic investigation.
Specifically, the data from this knock-out study allowed us to
differentiate PXR-dependent and independent mechanisms of this
BACE1 inhibitor in mediating the observed hepatotoxic effects.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and local animal
welfare bodies, and all animal work was approved by the Amgen’s
Institutional Animal Care and Use Committee under IACUC
protocol 2008-00174.
In vivo study
Two groups of mice, C57Bl/6 (PXR
+/+) and PXR-knockout
C57Bl/6NTac (PXR
2/2), were administered by oral gavage
either CMP013 or vehicle (2% HPMC/1% Tween 80 in DI
water, pH 2.2. adjusted with methanesulfonic acid) according to
dose levels outlined in Table 1. Food (irradiated Harlan Teklad
rodent maintenance diet) and water were available ad libitum
during the study except for the last 3–4 h prior to necropsy during
which animals were fasted and only water was available. Actual
food intake and water consumption were not monitored for
individual animals during the course of study. At 96 h, all animals
Figure 1. Effect of CMP013 on liver weight of wild type and
PXR-knockout mice. Wild type mice showed similar liver weight
increase as previously observed in Sprague Dawley rats; such increase
was absent in the knockout strain.
doi:10.1371/journal.pone.0015595.g001
Table 1. Study Design.
Strain Test Article Dose level (mg/kg/day) Dose volume (mL/kg) Concentration (mg/mL)
C57Bl/6 (WT) Vehicle
a 01 0 0
C57Bl/6 (WT) CMP013 150 10 15
C57Bl/6NTac (PXR-KO) Vehicle
a 01 0 0
C57Bl/6NTac (PXR-KO) CMP013 150 10 15
All animals were 9-week old males at initiation of treatment. Mice were dosed via oral gavage every 24 h and euthanized at 96 h. Each of the following groups contains
5 animals.
a2% HPMC/1% Tween 80 in DI water, pH 2.2. adjusted with methanesulfonic acid.
doi:10.1371/journal.pone.0015595.t001
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tion. Liver samples were promptly collected and frozen until ready
for RNA extraction.
RNA Isolation
Total RNA was isolated from pieces of mouse liver according to
the RNeasy extraction procedure (Qiagen, Valencia, CA). Tissues
were homogenized in QIAzol lysis buffer using the GenoGrinder
2000 homogenizer (SPEX SamplePrep, Metuchen, NJ). Samples
were processed on the Qiagen BioRobot Universal system
according to the manufacturer’s instructions. An on-column
DNase digestion was performed to remove any residual genomic
DNA contamination. RNA concentration and yield were mea-
sured spectrophotometrically using the Nanodrop instrument.
Quality of the nucleic acid samples was evaluated with the RNA
6000 Nano chip kit (Agilent Technologies, Expert software).
Quality of samples was verified with distinct ribosomal 18S & 28S
peaks, low baseline, and high RIN values (PXR
+/+: 9.3-10;
PXR
2/2: 8.7-9.6).
Gene expression data generation
Liver RNA from individual mice was profiled separately on the
Affymetrix GeneChipH platform without technical replication.
Microarray profiling was performed by Cogenics (Morrisville,
NC). Briefly, 1 mg of total RNA was reverse transcribed to double
stranded cDNA with the BioarrayTM Single-Round RNA
Amplification and Labeling Kit and biotinylated cRNA was
generated using the BioArray
TM HighYield
TM RNA Transcript
Labeling Kit (Enzo Life Sciences, Farmingdale, NY). For each
sample, 10 mg of biotinylated cRNA spiked with hybridization
controls (bioB, bioC, bioD and cre) was hybridized to an
Affymetrix Mouse 430_2 microarray for 16 h at 45uC. Following
hybridization, arrays were washed and stained in an Affymetrix
GeneChip Fluidics Station and scanned with a GeneChipH
Scanner 3000 (Affymetrix, Santa Clara, CA). Quality checks and
data analyses were carried out using Affymetrix GeneChip
Operating Software (GCOS) and Quality Reporter. All data were
MIAME compliant and raw data (cel files) have been deposited to
a MIAME compliant database, GEO, accession GSE23780.
Gene expression analysis
Analysis with the proposed method. Log-ratios of gene
expression data and associated platform p-values [11] were
generated in the Rosetta Resolver System (Rosetta Biosoftware,
Seattle, WA, version 7.2) for all profiles relative to strain-matched
vehicle-treated controls. For each Affymetrix sequence (or probe set),
log-ratio was defined to be the log10 of the intensity ratio of each animal
(either treated with vehicle or CMP013) to the mean intensity of that
sequence across the five profiles in the corresponding vehicle control
group. To identify differentially expressed sequences due to CMP013
treatment, we carried out a two-step non-parametric statistical analysis,
which was applied to data from wild type (WT) and PXR-knockout
(PXR-KO) mice separately. Thisa n a l y s i sw a sp e r f o r m e di nt h e
programming language R.
Step 1: Counting the number of samples in which a sequence i
showed differential expression based on platform p-value and fold
change. For each sequence, we identified the number of samples
that satisfy |log-ratio|$0.097 (equivalent to a fold change cutoff
of 1.25) and platform p-value #0.1. The number of animals
passing this criterion was counted separately for the vehicle and
the CMP013-treated groups (Equation 1)
Nvehicle
i ~max
jSj where S~fn j In
i § 0:097 ^ Pn
i ƒ 0:1g
jRj where R~fn j In
i ƒ {0:097 ^ Pn
i ƒ 0:1g
 
ð1Þ
where In
i is the log-ratio intensity of gene i measured in animal n,
Pn
i is the associated p-value of gene i, and Nvehicle
i represents the
number of animals satisfying the above conditions for sequence i in
the vehicle group. NCMP013
i is defined similarly for animals in the
treatment group. |S| represents the number of animals in which
sequence i was potentially up-regulated relative to the control pool,
while |R| represents the number of animals in which that
sequence was potentially -down-regulated. For each of WT or PXR-
KO dataset, this step produced two vectors of length equal the
number of sequences on the GeneChipH (Figure 2). In cases where
|S|=|R|, i.e., the genes show increased and decreased
expression in equal number of animals, such expression change
was designated non-interpretable and step 2 was not necessary.
Step 2: Estimate of statistical significance for group difference
between treatment and vehicle. A gene is identified as having
significantly altered expression by CMP013 treatment if a
significantly greater number of animals in the treatment group
satisfy the criteria in step 1 as compared to those in the control
group. In other words, we need to evaluate the probability of
getting a pairing of (Nvehicle
i ,NCMP013
i ) by chance. The null
hypothesis for a sequence i is that, for a givenNTotal
i =t, the
numbers of animals that satisfied conditions in step 1 are equally
distributed between the vehicle (NVehicle
i ) and treated group
(NCMP013
i ) (Equations 2–4). The values for t range from 0–9
because conditions for significance are set relative to the mean of
Figure 2. Counting procedure defined by step 1. In this diagram, colored circles represent profiles (animals) in which a sequence i satisfies |fold
change|$1.25 and platform p-value #0.1, while open circles represent samples that do not. A red circle symbolizes up-regulation and a green circle
symbolizes down-regulation. The counting step simply records a sum of the number of profiles showing changed in the same direction.
doi:10.1371/journal.pone.0015595.g002
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this group is 4.
E NCMP013
i jNTotal
i ~t
  
~1=2t ð2Þ
NTotal
i ~NVehicle
i zNCMP013
i ð3Þ
t[ 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 fg
A sequence i is deemed significantly differentially expressed by
CMP013 if NCMP013
i is equal or larger than a cutoff, which is
determined by controlling the false discovery rate (FDR). A null
distribution was created by permuting the profile labels among
vehicle and treated groups 252 times (exhaustive combinations)
and re-computing step 1 on this randomized data. For a given
number of significant samples j in treated group, with NTotal =t,
the FDR is given by Equation 4.
FDRtj~medianoverall permutations
P
k§j
n
perm
tk
P
k§j
nobs
tk
0
B @
1
C A ð4Þ
The denominator in the fraction represents the number of genes
that would be considered significant from observed data; the
numerator represents the number of genes considered significant
from permutation. Sequences with FDRtj#0.05 were considered
statistically significant (Table 2).
Analysis with SAM. SAM analysis was carried out using the
method sam in the Bioconductor [16] package siggenes. The input
was a data frame containing log2 intensity of 10 profiles (vehicle
and treatment) in either the WT or PXR-KO dataset. The class
label was a vector of 10 elements, assigning zeros for vehicle and
ones for treatment profiles. The default method d.stat (a modified t-
test) as defined by Tusher et. al. [12] was applied as the test
statistics. The output of sam was a table containing a list of 10 delta
cutoffs, the number of genes deemed statistically significant at
these cutoffs and associated FDR. We used this table to fine tune
delta values so that the final FDR was ,10% below the desired
FDR of 0.05. The resulting gene lists for both WT and PXR-KO
data were used for pathway analysis.
Pathway Analysis
Pathways associated with differentially expressed genes identi-
fied by our proposed algorithm and SAM were analyzed using the
Tox Analysis function in IPA (Ingenuity Systems, Redwood City,
CA) [Application version: 8.0, Build: 82437; Content version:
2602]. Canonical pathways and tox list (list of genes associated
with toxicities as determined by IPA) with p-value #0.05 were
deemed significantly perturbed pathways.
Results
Identification of differential expressed genes due to
CMP013 treatments
Results obtained with current method. The Mouse
Affymetrix 430_2 GeneChipH contains 45,037 probe sets, which
we refer to as sequences in this paper. The principle component
analysis (46% explained, Figure 3) of these sequences, based on
quantile-normalized intensity data, showed that separation was
observed for animals treated with vehicle vs. CMP013. In fact, the
effect of CMP013 treatment appeared much larger than the effect
of knocking out PXR, highlighting the fact that this compound
modulated a relatively large number of genes in mouse liver.
Log-ratio data and associated platform p-values for all
sequences were generated in Rosetta Resolver (version 7.2).
Results with the current method showed that CMP013 led to
4,213 and 3,369 differentially expressed sequences in the livers of
WT and PXR-KO mice, respectively (Figure 4, Data S1). In the
WT model, the majority of sequences differentially expressed by
CMP013 were changed in all five animals in the treatment group.
In the PXR-KO model, however, the majority of differentially
expressed sequences were changed in only three animals in the
treatment group. This suggested that the transcriptional response
to CMP013 in PXR-KO mice was less homogeneous than that in
WT mice. We speculated that the difference in group behaviors
between the knockout and WT strains was a result of different
compensatory mechanisms each knockout animal developed to
compensate for the absence of PXR regulation. There was not
sufficiently strong evidence to support this hypothesis in the
current study, but we are investigating mouse strains with
knockout of other nuclear receptors to determine if similar
behaviors are exhibited. Nevertheless, our method is particularly
well-suited for studies in both preclinical and clinical settings
where subject-to-subject variation is relatively large. Overall, we
Table 2. False discovery rate (FDR) estimated based on wild-
type (A) and PXR-knockout (B) data.
A W T 0 12345
0 1
1 10 . 5 5 8
2 1 0.827 0.227
3 1 0.925 0.500 0.058
4 1 0.975 0.781 0.183 0.001
5 1 0.993 0.983 0.484 0.003 0
6 1 0.993 0.990 0.692 0.044 0
7 1 0.980 0.980 0.843 0.144 0
8 1 0.947 0.947 0.842 0.333 0
9 1 1110 . 5 0
B PXR-KO 0 12345
0 1
1 10 . 6 3 2
2 1 0.831 0.225
3 1 0.897 0.473 0.028
4 1 0.938 0.808 0.080 0.001
5 1 0.973 0.948 0.404 0.005 0
6 1 0.979 0.973 0.642 0.046 0
7 1 0.977 0.977 0.826 0.217 0
8 1 1 1 0.923 0.385 0
9 1 1110 . 5 0
Each value Fij in the table indicates the FDR for a gene found to be differentially
expressed (based on fold change and platform p-value cutoffs) in j samples of
the CMP013 treatment group out of i samples that are differentially expressed
in both groups. Underlined values correspond to cases where the genes would
be considered statistically significant at FDR#0.05. FDR=0 corresponds to
events that were not observed in permutated data.
doi:10.1371/journal.pone.0015595.t002
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CMP013 treatment in the WT model as compared to the PXR-
KO model. In addition, most of these sequences appeared to be
strain-specific: 76% of sequences changed in the WT model were
found only in this model and 70% of sequences changed in the
PXR-KO model were unique to that model. About 18% of the
total number of differentially expressed sequences in WT mice
were similarly modulated (either up-regulation or down-regula-
tion) in PXR-KO mice; these sequences and associated genes were
considered to represent PXR-independent effects.
Comparison with results obtained with SAM. SAM
returned 5,202 differential expressed sequences in CMP013-
exposed WT mice and 2,300 sequences in the PXR-KO mice
(Figure 4, Data S1). That is, at a false discovery rate of 5%, SAM
identified more sequences than our proposed method in the WT
model, and we identified more sequences than SAM in the PXR-
KO model. In designing our analysis, we wanted to give
considerations to both biological and statistical significance. The
key difference between the proposed method and SAM is that our
method used a threshold approach to determine biological
significance and group effect to determine statistical significance
determination. In addition, we did not penalize large variation of
changes within the same treatment group as long as the changes
were in the same direction. As a result, though SAM returned
approximately 20% more statistically significant sequences than our
method in the WT model; the vast majority of them (85%) did not
satisfy a fold change cutoff of 1.25. While such changes were
sufficiently homogenous among animals in the same treatment
group to achieve statistical significance; the increase or decrease
might be too small to warrant biological difference. On the other
hand, the proposed method identified 1,214 additional sequences
that were not returned by SAM. These sequences were more likely
to represent significant biological differences because their
expression changes, though varied from animal to animal, were in
the same direction. Furthermore, since there were more non-
responders in the PXR-KO group, the current method was more
sensitive than SAM and was able to return many sequences which
did not express large differential expression in 1–2 animals. In other
words, the SAM method is less sensitive when group behavior is less
consistent. Heat maps of sequences identified only by the current
method orSAMfurtherillustrate the differences inresults ofthetwo
methods (Figure 5 C–F). Panels C and E show that sequences found
by our method have clear differential expression (due to fold change
cutoff) as compared to the control group even when the magnitude
of difference is relatively small. In contrast, panels D and F show
that a portion of sequences identified by SAM do not display visible
differential expression. That is, sequences identified only by our
Figure 3. Principle component analysis. The first three principle
components are based on log2 intensity and shown as four groups: (%)
WT, (O) PXR-KO, black: vehicle, red: CMP013 treatment.
doi:10.1371/journal.pone.0015595.g003
              
 
   
 
 
 
 
Figure 4. Differentially expressed genes in CMP013-treated C57Bl/6 (WT) and C57Bl6NTac (PXR-KO) mice. ‘‘CMP013 vs. vehicle’’
represents genes identified as differentially expressed due to CMP013 treatment; ‘‘Changed in WT model only’’ represent genes that are likely
mediated by PXR in response to compound treatment; and ‘‘Changed in the same direction in two models’’ represents sequences that modulated by
the compound independent of PXR regulation.
doi:10.1371/journal.pone.0015595.g004
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whereas those identified only with SAM were likely sequences that
had less than 1.25 fold change but were consistent among all five
animals in the treatment group. As noted earlier, sequences in this
latter category could appropriately be considered to have
statistically significant differences, but such differences may not be
sufficient to constitute biological significance. It is, of course, up to
the investigator to decide how much change would constitute
biological difference, and the approach presented in this paper is
designed to be amenable to such modification.
Transcriptional effects of BACE1 inhibitor CMP013
We grouped CMP013-modulated sequences into two catego-
ries: A) sequences uniquely changed in the WT model, i.e., PXR-
Figure 5. Heat maps of differentially expressed genes identified by the proposed method and SAM. Panels A and B show genes that
transcriptionally respond to CMP013 treatment in a PXR-dependent and independent manners. Panels C and E show the subset of genes identified
only by our proposed method and panels D and F show genes identified only by SAM.
doi:10.1371/journal.pone.0015595.g005
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between the WT and PXR-KO models, i.e., PXR-independent
response to CMP013 treatment. Sequences in group A were found
to be involved in PXR-mediated pathways, as their expression was
modulated only in WT mice and unchanged in the knockout
model (Figure 5A). Examination of this group of pathways in
relation to histopathology findings provided a clearer understand-
ing of PXR’s role in the dramatic hepatocellular hypertrophy
observed in WT mice. Sequences in group B reflected properties
of the compound that did not depend on the presence of PXR
(Figure 5B). These groups of sequences were transferred to IPA
where they were mapped to known genes and associated
pathways. It should be noted, however, that only about 50% of
sequences were mapped to annotated genes and pathways in IPA,
and thus our interpretation of these data was limited by this
annotation. When there were multiple sequences mapped to the
same gene symbol, the sequence with the largest fold change was
assigned to that gene.
PXR-dependent transcriptional effects. Parallel treatment
of wild type and PXR-KO mice with CMP013 allowed us to
elucidate transcriptional responses that were dependent on PXR
regulation. Knockout of the nuclear hormone receptor PXR
completely prevented the CMP013-induced increases in liver
weights, hepatocellular hypertrophy and mitotic activity.
Comparison of gene expression data obtained from two groups
of animals provided molecular evidence for many of these
changes. In particular, CMP013 increased the expression of
3,206 genes exclusively in WT mice, many of which were
indicative of PXR/CAR agonism properties of this compound. In
particular, there was increased expression of hallmark P450 genes
including Cyp3a4 (4.3 fold) and Cyp2b6 (88 fold). We additionally
observed induction of genes encoding phase 1 and 2 enzymes such
as aldehyde dehydrogenase (1a1, 1a7, 1b1, and 18a1, 1.5-2 fold),
glutathione S-transferase alpha (Gsta4, 4.5 fold; Gsta5, 11 fold),
glutathione S-transferase mu (members 1, 3, 4, 5 and 6; 1.3-11
fold), and UDP glucuronosyltransferase (Ugt2b10 and Ugt2b15,
,2 fold). Besides these xenobiotic metabolism genes, PXR
regulation also had roles in many hepatotoxicity-related cellular
processes with the notable ones described below.
Consistent with the hepatomegaly and liver weight increase
observations (Figure 1), altered expression of genes involved in
G1/S and G2/M cell cycle check points was observed in WT
mice. Increased expression of cyclin-dependent kinase 1 (Cdk1, 3.3
fold) and cyclin D1 (Ccnd1, 2 fold) suggested that CMP013
enabled a growth-induced condition, which allowed the cells to
overcome the G1/S checkpoint. Complexes involved Ccnd1 have
been reported to phosphorylate the tumor suppressor retinoblas-
toma, which in turn relieved the inhibition on the transcription
factor E2f [17,18]. Consistent with this report, we observed 2-3
fold increased expression of retinoblastoma-binding proteins
(Rbll), E2f3, and E2f6. The second checkpoint is located at the
end of G2 phase and the beginning of the M phase, which ensures
the cell’s readiness for mitosis. Though many proteins involved in
this process were regulated by post-translational modification,
transcriptional changes were observable for Chk1 checkpoint
homolog (Chek1, 2.9 fold) and cyclin B1 and B2 (Ccnb1, 2.2 fold;
Ccnb2, 4 fold). The induction of these genes underscored the role
of PXR in cellular proliferation as a likely contributor to the
profound liver weight increase observed in WT but not PXR-KO
mice.
The protein ubiquitination pathway plays a major role in the
degradation of regulatory proteins involved in cell cycle, apoptosis,
and a variety of signaling processes in the cell. In WT mice treated
with CMP013, we observed an increase in proteasomal degrada-
tion evidenced by the transcriptional changes of genes encoding
these enzymes. The degradation of proteins via the protein
ubiquitination pathway begins with the conjugation of multiple
ubiquitin (Ub) moieties to the target protein followed by the
degradation of the polyubiquitinated protein by the 26S protea-
some complex. Though expression changes in Ub-activating
enzyme (E1) were not observed, altered expression was noted for
numerous Ub-conjugating enzymes E2 (2f, 2k, 2l, 2m and 2v
increased ,1.5 fold; 2b, 2d, 2e, 2i, and 2n decreased 1.3-2 fold),
Ub protein ligase E3 (Ube3a, 1.6 fold increase), and ubiquitination
factors E4 (Ube4a and 4b, ,1.5 fold), which participated in multi-
Ub chain assembly. The polyubiquitin chain was recognized by
the multi-catalytic proteasome complex which completed the
proteolysis process. Transcriptional increase of genes making up
the proteasome complex was accordingly observed (Psma, Psmb,
Psmc, Psmd, and Psme, 1.3-2 fold).
Significant up-regulation of aminoacyl-tRNA biosysnthesis was
also observed exclusively in WT mice. Approximately two fold
transcriptional increase was noted for tRNA of most amino acids
including ala-tRNA synthetase (Aars and Aarsd1), arg tRNA
synthetase (Rars), asp tRNA synthetase (Nars), glu-tRNA synthe-
tase (Ears2), ile-tRNA synthetase (Iars), leu-tRNA synthetase
(Lars), lys-tRNA synthetase (Kars), phe-tRNA synthetase (Farsa),
and trp-tRNA synthetase (Wars) The increased transcription in
this process together with similar increases in the ubiquitination
pathway indicated that CMP013 led to a high rate of protein
turnover in the cells, likely associated with cell division.
Furthermore, CMP013 was associated with transcriptional
modulation of genes that were suggestive of an activation of the
NFkB signaling pathway in WT mice treated with CMP013. In
particular, we observed increased expression of TGFa (1.4 fold),
toll-interleukin 1 receptor domain containing adaptor protein
(Tirap, 1.3 fold), TNF receptor-associated factor 3 (Traf3, 2 fold),
eukaryotic translation initiation factor 2-alpha kinase (Eif2ak2, 1.7
fold), and inhibitor of kappa light polypeptide gene enhancer
(Ikbkg, 1.7 fold). The activation of this signaling pathway was
suggestive of an inflammatory response and was consistent with
the severity and frequency of the inflammatory infiltrates observed
in this group of mice.
PXR-independent transcriptional effects. We identified
754 sequences that were perturbed in the same direction in both
WT and PXR-KO mice treated with CMP013. Genes associated
with these sequences were mapped to five biological processes. In
addition to this shared gene set, we observed groups of
differentially expressed genes that were unique in each model of
mice, but were mapped to these same five pathways (Table 3).
A notable common response to CMP013 between WT and
PXR-KO mice was the down-regulation of genes involved in fatty
acid metabolism. In particular, decreased expression was observed
for key enzymes in b-oxidation including acyl-CoA dehydrogenase
(Acads, -1.4 fold in both models), which catalyzes the initial step in
each cycle of b-oxidation; and acetyl-CoA acyltransferases (Acaa1
and Acaa1b, both genes: -1.3 fold in WT, -1.6 fold in PXR-KO),
which catalyze the final step of the b-oxidation cycle. We
additionally observed transcriptional decrease in isoforms of these
genes as well as related genes in fatty acid metabolism; these genes
were unique to each mouse model. In the WT model, decreased
expression of -1.3-3 fold was noted for carnitine palmitoyltranfer-
ase (Cpt1a, -1.4 fold), acyl-CoA dehydrogenase, short and
branched chain (Acadsb, -2.6 fold), and acetyl-CoA acyltranferase
2 (Acaa2, -1.3 fold). In the PXR-KO model, decreased expression
of -1.3-2 fold was observed for acyl-CoA synthetase (Acad8, -1.6
fold), acyl-CoA oxidase 3 (Acox3, -1.4 fold), and enoyl-CoA
hydratase (Ehhadh, -1.3 fold). Collectively, these data suggested
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perturbation of mitochondrial b-oxidation and that this effect did
not necessitate PXR mediation. Additionally, CMP013 led to
increased biosynthesis of cholesterol in both mouse strains.
Evidence of this increase included the ,2 fold increased
expression of the rate limiting enzyme HMG-CoA reducatase
(Hmgcr) and numerous genes in this pathway such as mevalonate
kinase (Mvk), squalene epoxidase (Sqle), isopentenyl-diphosphate
delta isomerase 1 (Idi1), and farnesyl diphosphate farnesyl
transferase 1 (Fdft1). Similar increases in expression were noted
for other genes in the pathway, though the changes were only
observed in WT mice: lanosterol synthase (Lss), farnesyl
diphosphate synthase (Fdps) and 7-dehydrocholesterol reductase
(Dhcr7). Besides cholesterol, metabolism of other C21 steroids,
relating to androgen and estrogen metabolism, appeared to be
down-regulated with 1.3-21 fold decreased expression of multiple
hydroxysteroid dehydrogenases (Hsd3b1, Hsd3b3, Hsd3b4,
Hsd3b5, Hsd3b7, and Sdr42e1), and steroid-5-alpha-reductase
(Srd5a1, -1.5 fold). Perturbations related to cholesterol and its
derivatives might be associated with cellular stress responses
further described below.
In both mouse strains, CMP013 treatment was associated with
molecular evidences of reactive oxygen species (ROS) generation
and an oxidative stress response in the cell. Aside from the
induction of numerous phase 2 enzymes that had roles in elimina-
ting ROS, Nrf2 also coordinated the transcriptional increases of
antioxidant genes such as NAD(P)H dehydrogenase, quinone
1(Nqo1, 2.4 fold in WT, 1.7 fold in PXR-KO), and kelch-like
ECH-associated protein 1 (Keap1, 1.4 fold in WT, 1.3 fold in
PXR-KO). In the WT model, we further observed the transcrip-
tional increases of glutathione peroxidase 2 (Gpx2, 3.5 fold),
glutathione reductase (Gsr, 3.1 fold), thioredoxin (Txn, 1.4 fold),
and DnaJ (Dnajb2, Dnajb6, Dnajb9, Dnajc2, 1.3-2 fold). In PXR-
KO mice, increased expression was observed for thioredoxin
reductase 1 (1.4 fold PXR-KO), heme oxygenase (Hmox1, 2.8
fold), flavin containing monooxygenase (Fmo1, 1.5 fold), perox-
iredoxin 1 (Prdx1, 1.4 fold), and multiple DnaJ (a2, b1, b4, b6, c1,
c2, c3, and c10, ,1.5 fold). Furthermore, evidence for pertur-
bations in the endoplasmic reticulum (ER) function was noted with
the altered expression of genes signaling ER stress. In particular,
we observed increased expression of eukaryotic translation
initiation factor 2-alpha kinase 3 (Eif2ak3 or Perk, 1.4 fold in
WT, 1.6 fold in PXR-KO), the ER stress sensor activating
transcription factor 6 (Atf6, 1.3 in WT, 1.8 fold in PXR-KO),
membrane-bound transcription factor peptidase, site 2 (Mbtps2 or
S2p, 1.4 fold in WT, 1.7 fold in PXR-KO), and Mapk8 (1.6 fold
WT, 1.7 fold in PXR-KO). These collective transcriptional
changes suggested that such ER stress was associated with an
Table 3. Comparison of differentially expressed genes
identified by the proposed method and SAM.
Wild type PXR-KO
Gene
Proposed
Method SAM
Proposed
Method SAM
Fatty acid metabolism
ACAA1 21.368 21.368 21.619 21.619
ACAA1B 21.337 21.337 21.642
ACAA2 21.318
ACAD8 21.545 21.545 21.622 21.485
ACADS 21.411 21.427
ACADSB 22.616 22.616 21.856
ACOX3 21.382 21.382
ACSL1 21.451 22.093 22.482 22.482
CPT1A 21.402 21.339
EHHADH 21.332
Cholesterol biosynthesis
DHCR7 1.692 1.692
FDFT1 2.498 1.862 1.345 1.345
FDPS 1.366
HMGCR 2.631 2.631 1.55
HMGCS1 10.515 10.515 2.985
IDI1 1.544 1.445 1.815 1.815
LSS 2.303 2.303
MVD 5.342 5.342
MVK 2.633 2.633 2.968 2.968
SQLE 1.945 1.945 1.242
Oxidative Stress
DNAJA2 1.439
DNAJB9 2.367 2.367 1.962 1.962
DNAJC2 1.965 1.965 1.533
FMO1 1.547 1.547
GPX2 3.464 3.464
GSR 3.065 3.065
HMOX1 2.848 2.848
KEAP1 1.445 1.445 1.268
NQO1 2.392 2.392 1.741 1.741
PRDX1 1.35
TXN 1.413 1.36
TXNRD1 1.423
Endoplasmic reticulum signaling
ATF4 1.64
ATF6 1.308 1.811 1.811
EIF2AK3 1.416 1.61 1.61
MAPK8 1.557 1.686
MBTPS2 1.369 1.663
Bile acid signaling
ABCB1 3.761 3.177 2.89 2.89
ABCC2 1.927 1.927
ABCC3 2.432 2.432 1.325 1.325
CYP7B1 21.876 21.876
CYP8B1 21.933 21.933
Wild type PXR-KO
Gene
Proposed
Method SAM
Proposed
Method SAM
SLCO1A2 11.494 7.756
Below are five biological processes and associated genes that were commonly
modulated in both WT and PXR-KO mice after 96 h treatment with CMP013.
Values in each row are averaged fold change of the gene across all five animals
in the treatment group. Fold change values of a gene may differ between the
proposed method and SAM if each method identifies a different Affymetrix
sequence corresponding to the same gene as significant.
doi:10.1371/journal.pone.0015595.t003
Table 3. Cont.
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the rate of protein translation to prevent the accumulation of
unfolded proteins (via the action of Perk and its target eukaryotic
initiation factor 2, eIF2) and activating regulated intramembrane
proteolysis [19] (via the action of Atf6 and S2p). There appears to
be an interesting relationship between ER stress and increased
cholesterol biosynthesis. Previously, Lee et. al. reported that ER
stress inhibited the synthesis of Insig-1 protein, which in turns
allowed Srebp proteolytic activation even in the presence of sterols
[20]. The authors used cultured cells transfected with human
Insig-1 and Insig-2 and herpes simplex virus Srebp2; here we were
observed a similar phenomenon in vivo.
Lastly, there were perturbations in bile acid homeostasis
associated with CMP013 exposure in both WT and PXR-KO
models. Alteration to biliary transport was noted with increased
expression of the canalicular transporters Abcb1 (or Mdr1, 3.8
fold), the basolateral transporter Abcc3 (or Mrp3, 2.4 fold), and
the basolateral uptake transporter Slco1a2 (or Oatp, 11 fold).
Increased expression of Mrp3 observed in the PXR-KO model
suggested that another nuclear receptor was compensating for
PXR in regulating bile acid homeostasis. In WT mice, we further
observed increased expression of the canalicular transporter Abcc2
(Mrp2, 1.9 fold). In PXR-KO mice, Cyp7b1, encoding oxysterol
7alpha-hydroxylase, which converted cholesterol to bile acids,
decreased 1.5 fold in expression. Cyp8b1, encoding the enzyme
sterol 12-alpha-hydroxylase, which controls the balance between
cholic acid and chenodeoxycholic acid secreted into the bile,
decreased 1.9 fold in expression. These transcriptional changes
indicated that CMP013 perturbed the transport and recycle of bile
acids and their conjugates in WT mice and affected the
biosynthesis and metabolism of bile acids in the knock-out strain.
Together, the changes were suggestive of a cholestatic response
induced by the compound [21].
Discussion
The present study describes a novel algorithm for analyzing
gene expression data and its application in studying the
mechanism of toxicity of a drug candidate. Results with the
proposed method were compared with analysis obtained with
SAM to identify strengths and weaknesses associated with the new
approach. First, a compelling aspect of our approach is that it is
straightforward in its assumptions and therefore would be
relatively easy for investigators to determine if the method is
suitable for their experiments or questions. The threshold proce-
dure in step 1 is simple and investigators can easily substitute an
alternate cutoff that constitutes biological significance in their
experiment. In the current study, by allowing a small cutoff on fold
change, we increase our sensitivity for subtle expression changes
because it is important, in toxicological assessment, to maintain a
low false negative rate, even at the expense of false positives. This
low threshold facilitates the discovery of signaling and regulatory
genes which can produce a large downstream effect with a small
change in expression. In fact, as most regulatory proteins are
regulated by post-translational modification, only a small tran-
scriptional increase is necessary to supplement the allosteric
changes of the proteins. As compared to results obtained with
SAM, the current method produced improved results in at least
two pathways. For example, none of the genes in the ER stress
response were found with SAM in WT mice. These genes have
relatively small fold change (1.25 – 1.5), but the combined increase
of multiple genes in this pathway strongly suggests that the ER
stress response is not insignificant. The second example involves
the cholesterol biosynthesis pathway in PXR-KO mice (Table 2).
The current method identifies six genes while SAM only identifies
three as differentially significant. Since pathway mapping by IPA is
determined by the Fisher’s Exact test, the presence or absence of
these few genes may affect whether the pathway is considered
activated. In looking at differentially expressed genes mapped to
canonical pathways (Table 3), we noted that the overlap between
results of the non-parametric method and SAM was much higher
(,70% as opposed to 45–55% in Figure 5). A possible explanation
for this is that genes with annotation tend to be those that have
been easily detected, resulting in their better characterization in
the literature, and this robustness to measurement is also reflected
in our study.
Inherent to the threshold approach in step 1 is that the current
procedure accounts only for directional changes and disregards
any differences in magnitude of changes as long as the fold change
cutoff is satisfied. In other words, the method does not use the level
of mRNA measured to determine if one pathway is more strongly
up or down regulated than others. Our rationale for this is two
fold. First, since the levels of mRNA fluctuate rapidly, it is usually
not possible to make an accurate determination of the level of
induction based on measurements at limited time points. That is,
beyond a threshold of fold change used to signify biological
difference, information on the magnitude of expression change is
likely to be highly dependent on the exact time of measurement
and therefore is not a reliable indicator of relative level of pathway
activation. Second, even when such ranking of pathway activation
can be determined, this information does not always improve the
overall understanding of the underlying biology since only
qualitative information about pathway modulation, i.e., whether
a pathway is up- or down-regulated, is transferable across
experiments. Alternative to the magnitude of change, we believe
that the statistical significance of modulation can be more reliably
estimated based on the consistency and similarity of responses
from animals in the same cohort. Accordingly, perhaps a
disadvantage of this method is that it necessitates at least five
animals per treatment group and does not perform well with small
group sizes. Similar to SAM and many other non-parametric
statistics, the null distribution is created by permuting sample
labels. Given an experimental design of two groups, sample
permutation of group size of four produces maximally only 70
different possibilities, and this number, from our experience, is too
small to generate a sufficiently informative null distribution for
FDR estimation. In the drug development setting, the requirement
of group size larger than three makes the method somewhat
impractical for many screening studies where the group size may
be limited to three, given the large number of drug candidates and
the intent for these studies. However, for most investigational and
mechanism identification studies, the number of animals per group
tends to be larger and thus more suitable for this method.
Finally, perhaps another undesirable aspect of the threshold
procedure is that it does not deal well with sequences which show
increased and decreased expression in equal number of animals.
In fact, we have resolved these situations by pre-filtering out all
such genes from consideration as differentially expressed (Mate-
rials & Methods section). With methods in which absolute levels of
expression are evaluated, it is possible that the genes could be
considered differentially expressed if the magnitude of change in
one direction far exceeds that in the other direction. In fact,
looking at genes that were only identified by SAM, we found
approximately 100 genes falling in this category (extreme ends of
Figure 5DF). These genes in vehicle-treated animals showed
mixed increased and decreased expression relative in the group
mean, but the genes were identified as differentially expressed
because the inter-group difference far exceeds intra-group
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perhaps a drawback of the current method. However, given the
uncertainty associated with magnitude of expression changes as
discussed above, it is unlikely that all of these genes are associated
with true signals. It is noteworthy to mention that if such genes
were associated with a true signal, one may still be able to realize
the associated biological response by the expression of other genes
involved in the same pathway. We therefore feel that the
elimination of such genes does not necessarily impact our overall
interpretation of the experiment. Our best recommendation in
these situations would be to apply our analysis method in
conjunction with an algorithm similar to SAM, i.e. using two
methods that have complementary approaches, so that one can
obtain a clear picture of the overall transcriptional response.
In summary, we describe a novel non-parametric statistical
method for the analysis of gene expression data for studies in
which conventional variance-based analysis methods result in
suboptimal results. Indeed, the benefit of our method is
substantiated for datasets from preclinical or clinical studies where
subject-to-subject variations are relatively large. The method is
straightforward in its assumptions and allows investigators to
specify criteria for both biological significance and statistical
significance. In the mouse-knockout example described here, the
application of this method allowed us to unravel the molecular
mechanisms associated with hepatic toxicities induced by an
inhibitor of b-secretase in the presence and absence of the nuclear
hormone receptor PXR.
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